Hack Remco J, Rutten Julie, Lesnik Oberstein Saskia AJ
Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
CADASIL (erebral utosomal ominant rteriopathy with ubcortical nfarcts and eukoencephalopathy) is characterized by mid-adult onset of recurrent ischemic stroke, cognitive decline progressing to dementia, a history of migraine with aura, mood disturbance, apathy, and diffuse white matter lesions and subcortical infarcts on neuroimaging.
DIAGNOSIS/TESTING: The diagnosis of CADASIL is established in a proband either by identification of a heterozygous pathogenic variant in by molecular genetic testing or, if molecular genetic testing is not definitive, by detection of characteristic findings by electron microscopy and immunohistochemistry of a skin biopsy.
There is no treatment of proven efficacy for CADASIL. Standard supportive treatment for stroke; the effect of thrombolytic therapy for the treatment of stroke remains unknown. Migraine should be treated symptomatically. Standard treatment for psychiatric disturbance. Supportive care (practical help, emotional support, and counseling) is appropriate for affected individuals and their families. : Antiplatelet therapy may be considered for prevention of stroke/TIA, but efficacy has not been proven. Anticoagulants should be avoided if possible. Control of vascular risk factors (hypertension, diabetes, hypercholesterolemia, smoking). Prophylactic treatment of migraines, depending on the frequency. Routine evaluation by a neurologist with expertise in CADASIL; consultation with a neuropsychiatrist if symptoms of depression, apathy, or psychiatric manifestations; consultation with other medical specialists (e.g., rehabilitation physician, clinical geneticist, physical therapist, and psychologist) as needed. Thrombolytic therapy (intravenous thrombolysis) and oral anticoagulants probably increase the risk of intracerebral hemorrhage in individuals with CADASIL. These agents should therefore only be used carefully and on a case-by-case basis. Smoking increases the risk of stroke. : There may be an increased risk for neurologic events in pregnancy during and shortly after delivery (puerperium); transient neurologic events (migraine with aura) have most commonly been reported.
CADASIL is inherited in an autosomal dominant manner. Most affected individuals have an affected parent; pathogenic variants appear to be rare. Each child of an affected person is at a 50% risk of inheriting the pathogenic variant and developing signs of the disease. Prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible if the pathogenic variant in the family is known.
伴有皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病(CADASIL)的特征为成年中期起病的复发性缺血性卒中、逐渐发展为痴呆的认知功能减退、有先兆的偏头痛病史、情绪障碍、淡漠,以及神经影像学检查显示的弥漫性白质病变和皮质下梗死。
诊断/检测:CADASIL的诊断通过先证者进行分子遗传学检测鉴定出杂合性致病变异来确立;若分子遗传学检测不明确,则通过皮肤活检的电子显微镜检查和免疫组织化学检测特征性表现来确立。
尚无已证实对CADASIL有效的治疗方法。对卒中进行标准的支持性治疗;溶栓治疗对卒中的疗效仍未知。偏头痛应进行对症治疗。对精神障碍进行标准治疗。对患者及其家人给予支持性护理(实际帮助、情感支持和咨询)。可考虑使用抗血小板治疗预防卒中/短暂性脑缺血发作(TIA),但疗效尚未得到证实。尽可能避免使用抗凝剂。控制血管危险因素(高血压、糖尿病、高胆固醇血症、吸烟)。根据发作频率进行偏头痛的预防性治疗。由擅长CADASIL的神经科医生进行常规评估;若出现抑郁、淡漠或精神症状,咨询神经精神科医生;根据需要咨询其他医学专家(如康复医师、临床遗传学家、物理治疗师和心理学家)。溶栓治疗(静脉溶栓)和口服抗凝剂可能会增加CADASIL患者脑出血的风险。因此,这些药物应谨慎使用且需逐案决定。吸烟会增加卒中风险。分娩期间及产后不久(产褥期)妊娠期间发生神经系统事件的风险可能增加;最常报告的是短暂性神经系统事件(有先兆的偏头痛)。
CADASIL以常染色体显性方式遗传。大多数患者有患病的父母;致病变异似乎很少见。患者的每个孩子继承致病变异并出现疾病体征的风险为50%。如果家族中的致病变异已知,则对高危妊娠进行产前检测和植入前基因检测是可行的。